Editas Medicine (EDIT) Expected to Release Earnings on Monday

Editas Medicine (NASDAQ:EDIT) is projected to post its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Editas Medicine to post earnings of ($0.21) per share and revenue of $4.54 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.12. The firm had revenue of $11.89 million for the quarter, compared to analysts’ expectations of $2.85 million. Editas Medicine had a negative net margin of 157.32% and a negative return on equity of 196.63%. On average, analysts expect Editas Medicine to post ($0.80) EPS for the current fiscal year and ($0.81) EPS for the next fiscal year.

Editas Medicine Price Performance

Shares of EDIT stock opened at $2.67 on Monday. Editas Medicine has a one year low of $1.66 and a one year high of $3.94. The company has a market capitalization of $410.06 million, a P/E ratio of -3.56 and a beta of 2.00. The company’s 50-day simple moving average is $2.76 and its two-hundred day simple moving average is $2.67.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on EDIT shares. LADENBURG THALM/SH SH initiated coverage on Editas Medicine in a research note on Tuesday, August 18th. They set a “buy” rating and a $6.00 price target on the stock. Weiss Ratings raised shares of Editas Medicine from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Guggenheim raised shares of Editas Medicine from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a report on Wednesday, September 23rd. Wall Street Zen raised shares of Editas Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Wells Fargo & Company raised shares of Editas Medicine from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $4.00 to $6.00 in a report on Thursday, October 8th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $5.83.

About Editas Medicine

Editas Medicine, Inc is a biotechnology company focused on developing genomic medicines using CRISPR-based gene-editing technologies. The company’s research platforms include CRISPR/Cas9 and CRISPR/Cas12a, which are designed to make precise changes to DNA and potentially treat diseases caused by genetic abnormalities.

Editas Medicine’s lead investigational program is reni-cel, formerly known as EDIT-301. Reni-cel is an ex vivo gene-editing therapy intended to treat sickle cell disease and transfusion-dependent beta thalassemia by modifying a patient’s blood-forming stem cells before they are returned to the body.